Genautica

Stefan Gruenwald

Managing Partner

Dr. Stefan Gruenwald's career in Life Sciences spans more than two decades. He is the Founder of Corporate Governance Partners (www.cgfunding.com), co-founder, seed investor and Chief Technology Officer of Diagnomics (www.diagnomics.com), co-founder and chair of the Scientific Advisory Board (SAB) at the DNA SEQ Alliance (www.dna-seqalliance.com), as well as Managing Partner at Genautica with over 20 years experience in the biotech industry in San Diego, CA. Dr. Gruenwald was the VP or R&D at PharMingen (91-97) and the VP R&D at Becton Dickinson (98-99). Later he was the founder of Orbigen (00-04) and involved in several merger / acquisitions. Academic degree: MD / PhD, his thesis earned "summa cum laude" and was elected as the "Best Thesis of the Year". He won the "Friends of Paul Ehrlich" Award.

Dr. Gruenwald is involved in technology scouting and evaluation for over 15 years. Partner in Venture Capital Private Equity Fund of Funds (Archimedes). Fluent in English and German. Studied Human Medicine, Biology and Physics at the Johann-Wolfgang-Goethe University in Frankfurt / Germany. Broad scientific knowledge in many disciplines, including Biotechnology and Nanotechnology.

Specialties: Biotechnology management, start-up company management, Fortune 100 company management, mergers and aquisitions, Venture Capital, Private Equity, Funds of Funds, International contacts, Russia, China. Nanotechnology Investment.

References:

Pfeifer GP, Gruenwald S, Boehm TLJ, Drahovsky D: Isolation and characterization of DNA cytosine 5-methyltransferase from human placenta. Biochim. Biophys. Acta 740: 323-330 (1983).

Gruenwald S, Drahovsky D: DNA-cytosine-5-methyltransferase from P815 mouse mastocytoma cells: "maintenance" and " de novo" activities are carried out by the same molecule. Int. J. Biochem. 16: 883-888 (1984).

Pfeifer GP, Gruenwald S, Palitti F, Kaul S, Boehm TLJ, Hirth HP, Drahovsky D: Purification and characterization of mammalian DNA methyltransferase by use of monoclonal antibodies. J. Biol. Chem. 260: 13787-13793 (1985).

Pfeifer GP, Spiess E, Gruenwald S, Boehm TLJ: Mouse DNA-cytosine-5-methyltransferase: sequence specificity of the methylation reaction and electron microscopy of enzyme-DNA-complexes. EMBO J. 4: 2879-2884 (1985).

Palitti F, Carotti D, Gruenwald S, Rispoli M, Whitehead EP, Salerno C, Strom R, Drahovsky D: Inactivation of de novo DNA methyltransferase activity by high concentrations of double-stranded DNA. Biochim. Biophys. Acta 910: 292-296 (1987).

Gruenwald S, Hernaiz Driever P, Hoelzer D, Drahovsky D: Reduced methyl group acceptance of 1-ß-D arabinofuranosylcytosine-containing DNA polymers. Biochim. Biophys. Acta 950: 366-373 (1988).

Pfeifer GP, Steigerwald SD, Gruenwald S: The DNA methylation system in proliferating and differentiated cells. Cell Biophysics 15: 79-86 (1989).

Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JYJ: Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J. 10: 857-864 (1991).

Bein G, Gruenwald S, Murre C: E2A and E2-2 are subunits of B-cell specific E2-box DNA binding proteins. Mol. Cell. Biol. 13(6): 3522-3529 (1993).

Chen LI, Nishinaka T, Kwan K, Kitabayashi I, Yokoyama K, Fu YHF, Gruenwald S, Chiu R: The retinoblastoma gene product Rb stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator. Mol. Cell. Biol. 14(7): 4380-4389 (1994).

Wu C, Liu H, Crossen R, Gruenwald S, Singh S: Novel green fluorescent protein (GFP) baculovirus expression vectors. Gene 190: 157-162 (1997).

Sang BC, Shi L, Dias P, Liu L, Wei J, Wang ZX, Monell CR, Behm F, Gruenwald S: Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Blood. 89: 2909-2914 (1997).

Juan G, Gruenwald S, Darzynkiewicz Z: Phosphorylation of retinoblastoma susceptibility gene protein assayed in individual lymphocytes during their mitogenic stimulation. Exp Cell Res: 239:104-110 (1998).